ArticleScientific reports2026
Cell adhesion molecule 1 is upregulated in connective tissue mast cells and potentially contributes in IgE-mediated degranulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mast cells are heterogeneous tissue-resident immune cells, with connective tissue mast cells (CTMCs) and mucosal mast cells in rodents exhibiting distinct phenotypes and activation profiles. Cell adhesion molecule 1 (CADM1), an immunoglobulin superfamily adhesion molecule, has been implicated in mast cell-nerve and mast cell-stromal interactions as well as in the pathogenesis of atopic dermatitis. Here, we investigated CADM1 function in CTMCs using a monoclonal antibody against the extracellular domain of CADM1, termed 3E1. CTMCs were differentiated from bone marrow-derived mast cells (BMMCs) by fibroblast coculture, where CADM1 expression was markedly upregulated compared with BMMCs. Treatment with 3E1 downregulated CADM1 expression and suppressed β-hexosaminidase release from IgE-sensitized, antigen-stimulated CTMCs by 18%, whereas BMMCs were unaffected. In addition, 3E1 reduced FM4-64-positive granule formation in activated CTMCs by 34.2% and 27.3% at 5 and 60 min, respectively. Confocal analysis further showed that 3E1 pretreatment decreased F-actin rearrangement in activated CTMCs by 66.2% at 5 min. In a passive cutaneous anaphylaxis model, intravenous 3E1 reduced dermal mast cell degranulation by 10.4%. These findings identify CADM1 as a regulator of IgE-mediated degranulation in CTMCs and demonstrate 3E1 as a valuable tool for dissecting mast cell heterogeneity in relation to tissue localization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.